MA-ALSYM-ENERGY
Alsym™ Energy, a developer of next-generation rechargeable batteries, today announced that it is emerging from stealth to offer energy storage solutions for electric vehicles (EVs), stationary storage, and marine applications. Alsym’s battery technology promises to provide the performance of lithium-ion batteries at a fraction of the cost and without the inherent risk of fire. The company’s batteries are also less sensitive to raw material shortages and price volatility due to their use of low-cost materials with robust supply chains.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615005167/en/
To accelerate the development of these affordable battery systems, Alsym is partnering with a leading India-based automaker in a joint effort to develop Alsym’s batteries for EVs. Conditional on key performance levels being met, the automaker will contract with Alsym to supply a minimum of 3 gigawatt hours (GWh) per year of battery systems for use in its products. Alsym is also in talks with companies in the marine shipping and electric two-wheeler markets to develop similar partnerships.
“Lithium is inherently flammable, and there are numerous risks that accompany all lithium-based battery technologies,” said Mukesh Chatter, CEO and Co-Founder of Alsym Energy. “Alsym Energy is on a mission to provide the world with cost-effective energy storage solutions using advanced, inherently non-flammable battery materials beyond lithium, made from non-toxic, readily available resources to power the growing mobility and stationary storage industries. We’re excited to work with industry partners to produce the next generation of batteries and to validate the innovations that will enable widespread access to clean electricity on a global scale.”
Alsym’s team of scientists and product developers is working to deliver and scale clean, energy-dense batteries that will be available at prices that are affordable to nearly anyone around the world. Founded in 2015, Alsym has raised $32 million to date from investors including Helios Climate Ventures.
“We’re seeing global competition to bring new batteries to market. Most companies are focused primarily on performance and put little thought into also making their batteries safer and more cost-effective—especially for the developing world where consumers are more price-sensitive,” said Nitin Nohria, Ph.D., Chairman of Alsym Energy’s Board of Business Advisors and former Dean of the Harvard Business School. “The team at Alsym Energy is working to ensure that their batteries not only meet performance expectations at reduced cost, but also avoid most of the supply chain challenges associated with lithium-based technologies. Not only are Alsym batteries sustainable, but the company’s business model is sustainable as well.”
The company estimates that Alsym batteries will cost less than half of current lithium-based batteries, enabling automakers to offer EVs at prices lower than comparable models with internal combustion engines. Using non-flammable, non-toxic materials removes many end-of-life concerns often associated with batteries, and Alsym batteries are much easier to recycle, helping ease the burden on waste processors, landfills, and others tasked with managing battery waste.
Alsym is currently in the process of developing a 500-kWh prototype manufacturing facility in Massachusetts. Because the materials used are non-flammable and non-toxic, Alsym batteries can be easily built in nearly any industrial site. They can also be made in existing lithium-ion battery factories with little to no retrofitting required, at lower operating cost and without the need for expensive dry rooms, fire locks, and solvent recovery systems.
About Alsym Energy
Alsym™ Energy is a leading developer of advanced low-cost, high-performance rechargeable batteries made from readily available materials that are inherently non-flammable and non-toxic, providing an economically viable alternative to lithium-based technologies. The company is focused on commercial development and mass production of batteries for use in applications including passenger electric vehicles and two-wheelers, marine shipping, and stationary energy storage to enable a zero-carbon future. To learn more, please visit www.alsym.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220615005167/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
